Gene Therapy Solutions (GTS-15)

Medical breakthroughs shouldn't break the bank and employers should never have to choose between the health of their employees and the success of their business.

Current State of the Market:

Employer Risk

Gene and Cell Therapy costs have reached up to $4.25 million dollars.

Expected Impact

In 2025 the expected number of Gene Therapy cases is 1 in every 150,000 members equaling a total cost of $36M.

Future Impact

Over the next 5 years the treatable population is expected to increase 11.5 times to nearly 50,000 patients in the US alone.

Watch our Amwins Gene Therapy Solutions (GTS-15) video to learn more about how our program works.

How it Works

Amwins Gene Therapy Solutions (GTS-15) offers reimbursement to group health plans and their coordinating stop-loss carrier for qualified claims. Qualifying reimbursements extend from the first dollar of group health plan expense up to specified limits for each covered therapy.

Our program distributes the reimbursement according to the stop-loss deductible. Following the adjudication of a qualified claim, our program reimburses the group health plan up to their specific deductible and the balance of the reimbursement is distributed to the associated stop-loss carrier.

The Amwins Advantage - Simple, comprehensive protection for your client

Meaningful Protection

First-dollar reimbursement is given to the plan sponsor and stop loss carrier

Portability

Changes in the underlying plan does not affect coverage terms

Industry Expertise

Amwins experts monitor the landscape of FDA approvals and make purposeful additions to the program, bringing value and positive improvements

Simplified Billing

Including the program fee in the stop-loss bill reduces administrative burden

Introducing Gene Therapy Solutions (GTS-15)